{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:28:58Z","timestamp":1768400938024,"version":"3.49.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1097\/ico.0b013e3182801645","type":"journal-article","created":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T17:26:52Z","timestamp":1359739612000},"page":"689-695","source":"Crossref","is-referenced-by-count":32,"title":["Inhibition of Corneal Neovascularization by Subconjunctival and Topical Bevacizumab and Sunitinib in a Rabbit Model"],"prefix":"10.1097","volume":"32","author":[{"given":"Byung-Yi","family":"Ko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-gook","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gun-woong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo-Sean","family":"Jean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam-Seob","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaeku","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-36-20210204","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/00003226-199811000-00008","article-title":"Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization.","volume":"17","author":"Cursiefen","year":"1998","journal-title":"Cornea"},{"key":"R2-36-20210204","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ophtha.2011.01.041","article-title":". Horizons in therapy for corneal angiogenesis.","volume":"118","author":"Maddula","year":"2011","journal-title":"Ophthalmology"},{"key":"R3-36-20210204","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1600-0420.2004.00312.x","article-title":"Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing.","volume":"82","author":"Gan","year":"2004","journal-title":"Acta Ophthalmol Scand"},{"key":"R4-36-20210204","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas.","volume":"41","author":"Philipp","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R5-36-20210204","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/ICU.0b013e3282f0ca54","article-title":"Anti-vascular endothelial growth factor therapy for ocular neovascular disease.","volume":"18","author":"Andreoli","year":"2007","journal-title":"Curr Opin Ophthalmol"},{"key":"R6-36-20210204","first-page":"264","article-title":"Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).","volume":"104","author":"Azar","year":"2006","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R7-36-20210204","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":". Corneal neovascularization.","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"R8-36-20210204","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","article-title":". Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization.","volume":"168","author":"Jo","year":"2006","journal-title":"Am J Pathol"},{"key":"R9-36-20210204","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbrc.2007.02.156","article-title":"Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.","volume":"356","author":"Roskoski","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"R10-36-20210204","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ajo.2010.04.024","article-title":". Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in animal model.","volume":"150","author":"Perez-Santonja","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R11-36-20210204","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","article-title":". Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.","volume":"48","author":"Bock","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R12-36-20210204","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":". Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R13-36-20210204","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization.","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R14-36-20210204","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/ICO.0b013e31815cf67d","article-title":". Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).","volume":"27","author":"Kim","year":"2008","journal-title":"Cornea"},{"key":"R15-36-20210204","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":". Inhibition of experimental corneal neovascularization by bevacizumab (Avastin).","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R16-36-20210204","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","article-title":". Inhibition of corneal neovascularization by subconjunctival bevacizumab (Avastin) in an animal model.","volume":"145","author":"Papathanassiou","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R17-36-20210204","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1755-3768.2008.01399.x","article-title":". Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.","volume":"87","author":"You","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"R18-36-20210204","first-page":"327","article-title":". In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokineticpharmacodynamic relationship.","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R19-36-20210204","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/jop.2006.22.213","article-title":"A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo.","volume":"22","author":"Takahashi","year":"2006","journal-title":"J Ocul Pharmacol Ther"},{"key":"R20-36-20210204","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/02713680600559564","article-title":". Experimental inhibition of corneal neovascularization by photodynamic therapy with verteporfin.","volume":"31","author":"Yoon","year":"2006","journal-title":"Curr Eye Res"},{"key":"R21-36-20210204","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0014-5793(03)00967-0","article-title":". Nitric oxide-dependent cytoskeletal changes and inhibition of endothelial cell migration contribute to the suppression of angiogenesis by RAD50 gene transfer.","volume":"553","author":"Kook","year":"2003","journal-title":"FEBS Lett"},{"key":"R22-36-20210204","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/j.1460-9568.2011.07641.x","article-title":". Altered Purkinje cell responses and calmodulin expression in the spontaneously ataxic mouse, Pogo.","volume":"33","author":"Lee","year":"2011","journal-title":"Eur J Neurosci"},{"key":"R23-36-20210204","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s004170050106","article-title":". Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.","volume":"236","author":"Kruse","year":"1998","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R24-36-20210204","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/ICO.0b013e318201405a","article-title":"Treatments for corneal neovascularization: a review.","volume":"30","author":"Gupta","year":"2011","journal-title":"Cornea"},{"key":"R25-36-20210204","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1442-9071.2007.01572.x","article-title":". Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis.","volume":"35","author":"Hosseini","year":"2007","journal-title":"Clin Exp Ophthalmol"},{"key":"R26-36-20210204","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0420.2007.01049.x","article-title":"; Tubingen Bevacizumb Study Group. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.","volume":"86","author":"Yoeruck","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"R27-36-20210204","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1167\/iovs.05-1071","article-title":". The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization.","volume":"47","author":"Dell","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R28-36-20210204","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1001\/archopht.1989.01070020575043","article-title":". Promotion of graft survival by photothrombotic occlusion of corneal neovascularization.","volume":"107","author":"Corrent","year":"1989","journal-title":"Arch Ophthalmol"},{"key":"R29-36-20210204","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":". The effect of topical bevacizumab on corneal neovascularization.","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"R30-36-20210204","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3109\/02713683.2011.635916","article-title":". In vivo, in vitro toxicity and in vitro angiogenic inhibition of sunitinib malate.","volume":"37","author":"Dib","year":"2012","journal-title":"Curr Eye Res"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0b013e3182801645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:34:43Z","timestamp":1621884883000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201305000-00036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e3182801645","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}